Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93.
Published January 29, 2020 · Recall initiated: January 7, 2020
Summary
FDA records drug Class II recall D-0792-2020, published January 29, 2020 and initiated January 7, 2020. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 16,944 bottles of 30 capsules; Lot: Lot # 3082876, exp. date January 2020 Lot # 3082877, exp. date January 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Distributor
- Product was distributed to wholesalers, distributors , retail pharmacies, charitable organizations and mail order pharmacies throughout the United States and the product may have been further distributed.
- Lot
- Lot # 3082876, exp. date January 2020 Lot # 3082877, exp. date January 2020
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACandesartan Cilexetil and Hydrochlorothiazide Tablets, USP 32 mg/12.5 mg, packaged in a) 90-count bottles (NDCOctober 28, 2020
- FDATacrolimus Capsules, USP 5mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDCApril 1, 2020
- FDASotalol HCL Tablets, USP (AF) 80 mg, 100 count bottles, Rx Only, Mylan Pharmaceuticals Inc. Morgantown, WVMarch 25, 2020
- FDANizatidine Capsules, USP 150 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5150-91.January 29, 2020
- FDARanitidine, 150 mg Tablets, a) 7 count, b) 14 count, c) 20 count, d) 30 count, e) 60 count; Rx, Only, H.J.January 29, 2020
- FDALIFEPAK 15 MONITOR/DEFIBRILLATOR that was either manufactured with or received an upgrade kit that containedJanuary 22, 2020
Questions about this recall
Was Nizatidine Capsules, USP 300 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5300-93. recalled?
Yes. FDA published recall D-0792-2020 on January 29, 2020. Reported hazard: CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.
What should I do if I have this product?
Voluntary: Firm initiated · Letter